Dynavax Technologies Ownership

DVAX Stock  USD 12.36  0.19  1.56%   
The majority of Dynavax Technologies outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Dynavax Technologies to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Dynavax Technologies. Please pay attention to any change in the institutional holdings of Dynavax Technologies as this could imply that something significant has changed or is about to change at the company.
 
Shares in Circulation  
First Issued
2003-03-31
Previous Quarter
154.5 M
Current Value
154.8 M
Avarage Shares Outstanding
45.7 M
Quarterly Volatility
51.8 M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Some institutional investors establish a significant position in stocks such as Dynavax Technologies in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Dynavax Technologies, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Dividend Paid And Capex Coverage Ratio is likely to rise to 25.73 in 2024. Common Stock Shares Outstanding is likely to rise to about 135.2 M in 2024. Net Income Applicable To Common Shares is likely to rise to about 353.6 M in 2024.
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
  
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dynavax Technologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
For more information on how to buy Dynavax Stock please use our How to Invest in Dynavax Technologies guide.

Dynavax Stock Ownership Analysis

About 100.0% of the company shares are held by institutions such as insurance companies. The book value of Dynavax Technologies was currently reported as 5.19. The company had not issued any dividends in recent years. Dynavax Technologies had 1:10 split on the 10th of November 2014. Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California. Dynavax Technologies operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 311 people. To learn more about Dynavax Technologies call the company at 510 848 5100 or check out https://www.dynavax.com.
Besides selling stocks to institutional investors, Dynavax Technologies also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Dynavax Technologies' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Dynavax Technologies' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.

Dynavax Technologies Quarterly Liabilities And Stockholders Equity

1.06 Billion

Dynavax Technologies Insider Trades History

Less than 1% of Dynavax Technologies are currently held by insiders. Unlike Dynavax Technologies' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Dynavax Technologies' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Dynavax Technologies' insider trades
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid

Dynavax Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Dynavax Technologies is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Dynavax Technologies backward and forwards among themselves. Dynavax Technologies' institutional investor refers to the entity that pools money to purchase Dynavax Technologies' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Eventide Asset Management, Llc2024-06-30
2.9 M
Tang Capital Management Llc2024-06-30
2.5 M
Great Point Partners Llc2024-06-30
2.4 M
Blair William & Co2024-06-30
2.4 M
Renaissance Technologies Corp2024-09-30
2.3 M
Millennium Management Llc2024-06-30
1.6 M
Mizuho Markets Americas Llc2024-09-30
1.4 M
Fisher Asset Management, Llc2024-09-30
1.4 M
Northern Trust Corp2024-09-30
1.3 M
Blackrock Inc2024-06-30
21.9 M
Deep Track Capital, Lp2024-09-30
12.5 M
Note, although Dynavax Technologies' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Dynavax Technologies Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Dynavax Technologies insiders, such as employees or executives, is commonly permitted as long as it does not rely on Dynavax Technologies' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Dynavax Technologies insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Deep Track Biotechnology Master Fund, Ltd. over three weeks ago
Insider Trading
 
Justin Burgess over three months ago
Acquisition by Justin Burgess of 20000 shares of Dynavax Technologies at 11.7 subject to Rule 16b-3
 
David Novack over three months ago
Acquisition by David Novack of 20000 shares of Dynavax Technologies at 5.42 subject to Rule 16b-3
 
Cano Francis over three months ago
Disposition of 3615 shares by Cano Francis of Dynavax Technologies at 11.93 subject to Rule 16b-3
 
Cano Francis over six months ago
Acquisition by Cano Francis of 7500 shares of Dynavax Technologies at 5.9 subject to Rule 16b-3
 
Cano Francis over six months ago
Acquisition by Cano Francis of 22500 shares of Dynavax Technologies at 11.79 subject to Rule 16b-3
 
Justin Burgess over six months ago
Acquisition by Justin Burgess of 8416 shares of Dynavax Technologies subject to Rule 16b-3
 
Robert Janssen over six months ago
Acquisition by Robert Janssen of 50000 shares of Dynavax Technologies at 12.48 subject to Rule 16b-3
 
John Slebir over six months ago
Disposition of 70000 shares by John Slebir of Dynavax Technologies at 12.48 subject to Rule 16b-3
 
John Slebir over six months ago
Disposition of 88000 shares by John Slebir of Dynavax Technologies at 11.12 subject to Rule 16b-3
 
John Slebir over six months ago
Disposition of 70000 shares by John Slebir of Dynavax Technologies at 12.48 subject to Rule 16b-3
 
Justin Burgess over six months ago
Acquisition by Justin Burgess of 20000 shares of Dynavax Technologies at 11.7 subject to Rule 16b-3

Dynavax Technologies Outstanding Bonds

Dynavax Technologies issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Dynavax Technologies uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Dynavax bonds can be classified according to their maturity, which is the date when Dynavax Technologies has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Dynavax Technologies Corporate Filings

13A
14th of November 2024
The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934
ViewVerify
8K
12th of November 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
F3
24th of October 2024
The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock
ViewVerify
13A
18th of October 2024
An amended filing to the original Schedule 13G
ViewVerify

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Dynavax Stock Analysis

When running Dynavax Technologies' price analysis, check to measure Dynavax Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dynavax Technologies is operating at the current time. Most of Dynavax Technologies' value examination focuses on studying past and present price action to predict the probability of Dynavax Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dynavax Technologies' price. Additionally, you may evaluate how the addition of Dynavax Technologies to your portfolios can decrease your overall portfolio volatility.